Glucagonoma differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 71: Line 71:
|-
|-
|[[Pemphigus foliaceus]] 
|[[Pemphigus foliaceus]] 
|It is an autoimmune blistering disease of the skin with characteristic lesions that are scaly, crusted erosions, often on an erythematous base.<sup>[[Pemphigus foliaceus#cite note-Fitz2-1|[1]]]</sup>
Mucosal involvement is absent even with widespread disease.<sup>[[Pemphigus foliaceus#cite note-Bolognia-2|[2]]]</sup>
The pathway is most likely either of three mechanisms:
* Steric hindrance of the desmoglein 1: The antibody caps off the site for intracellular binding to another keratinocyte.
* Activation of an endocytic pathway: The antibody activates a pathway which causes an internalization of desmoglein 1, which in turn causes a loss of adhesion.
* Disruption of function: In this case, the antibody blocks the desmoglein 1 from being formed into a desmosome. This, in turn, causes a loss of adhesion with acantholysis as a result.
|
|
|
* Pemphigus foliaceus is a superficial variant of pemphigus that presents with cutaneous lesions. [1]
|
* Pemphigus foliaceus usually develops in a seborrheic distribution.
* The scalp, face, and trunk are common sites of involvement. The skin lesions usually consist of small, scattered superficial blisters that rapidly evolve into scaly, crusted erosions
* The skin lesions may remain localized or may coalesce to cover large areas of skin. Occasionally, pemphigus foliaceus progresses to involve the entire skin surface as an exfoliative erythroderma [9].
* Pain or burning sensations frequently accompany the cutaneous lesions. Systemic symptoms are usually absent.
|Positive Nikolsky sign [10]
|If there is an autoimmune [[IgG]] build up in the [[Epidermis (skin)|epidermis]], then nearly almost all of the antibodies are aimed against [[desmoglein 1]]
|
|
|-
|-

Revision as of 14:59, 3 August 2017

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma differential diagnosis

CDC on Glucagonoma differential diagnosis

Glucagonoma differential diagnosis in the news

Blogs on Glucagonoma differential diagnosis

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Glucagonoma must be differentiated from certain skin lesions (acrodermatitis enteropathica, psoriasis, pellagra, eczema) and other causes of hyperglucagonemia (infection, diabetes mellitus, Cushing syndrome, renal failure, acute pancreatitis, severe stress, and prolonged fasting).

Differentiating Glucagonoma from other Disease

Glucagonoma must be differentiated from certain skin lesions in which necrolytic migratory erythema can be found and other causes of hyperglucagonemia:[1][2]

Disease Clinical Picture Investigations Pictures
History Symptoms Signs
Glucagonoma
  • The first peak for the development of psoriasis occurs between 20 years to 35 years and the second peak is between 40 years to 65 years of life.
  • Patients with early disease onset often have a positive family history of psoriasis, frequent association with histocompatibility antigen (HLA)- Cw6, and more severe disease. Those with onset after the age of 40 usually have a negative family history and a normal frequency of the HLA- Cw6 allele.[2]
  • A typical patient of psoriasis will present with a history of a long-term erythematous scaly area with ocular and joint involvement depending upon the clinical subtype and chronicity of the disease. There may be multiple relapses and remissions.
  • Past medical history of the patient may include viral or bacterial infection, diabeteshypertensionchronic kidney disease and/or obesity due to an association of psoriasis with these conditions.[3]
  • A social history of the patient may indicate smoking, excessive alcohol consumption and/or a recent stressful event if life associated with an acute exacerbation of psoriasis.[4]
  • A long-term history of erythematous scaly area, which may involve multiple areas of the body    
  • Pain, which has been described by patients as unpleasant, superficial, sensitive, itchy, hot or burning (especially in erythrodermic psoriasis and in some cases of traumatized plaques or in the joints affected by psoriatic arthritis) 
  • Pruritus (especially in eruptive, guttate psoriasis)
  • High fever
  • Dystrophic nails
  • Long-term rash with recent presentation of arthralgia
Skin biopsy

Perivascular and dermal inflammatory cell infiltration

Vascular dilation

Absent granular layer

Elongation of dermal papillae

Parakeratosis

Spongiform pustules of Kogoj (pathognomic of psoriasis)

Munro's micro abscesses (pathognomic of psoriasis)

Edema of dermal papillae

In psoriasis, skin biopsy of the affected area of skin shows that the epidermal/supra-papillary thickness ratio is increased

Basal cell layer is expanded

Leukocytosis

End-stage liver disease
Pemphigus foliaceus  It is an autoimmune blistering disease of the skin with characteristic lesions that are scaly, crusted erosions, often on an erythematous base.[1]

Mucosal involvement is absent even with widespread disease.[2]

The pathway is most likely either of three mechanisms:

  • Steric hindrance of the desmoglein 1: The antibody caps off the site for intracellular binding to another keratinocyte.
  • Activation of an endocytic pathway: The antibody activates a pathway which causes an internalization of desmoglein 1, which in turn causes a loss of adhesion.
  • Disruption of function: In this case, the antibody blocks the desmoglein 1 from being formed into a desmosome. This, in turn, causes a loss of adhesion with acantholysis as a result.
  • Pemphigus foliaceus is a superficial variant of pemphigus that presents with cutaneous lesions. [1]
  • Pemphigus foliaceus usually develops in a seborrheic distribution.
  • The scalp, face, and trunk are common sites of involvement. The skin lesions usually consist of small, scattered superficial blisters that rapidly evolve into scaly, crusted erosions
  • The skin lesions may remain localized or may coalesce to cover large areas of skin. Occasionally, pemphigus foliaceus progresses to involve the entire skin surface as an exfoliative erythroderma [9].
  • Pain or burning sensations frequently accompany the cutaneous lesions. Systemic symptoms are usually absent.
Positive Nikolsky sign [10] If there is an autoimmune IgG build up in the epidermis, then nearly almost all of the antibodies are aimed against desmoglein 1
Pustular psoriasis
Acrodermatitis enteropathica
Pellagra
Chronic eczema
kwashiorkor

References

  1. Glucagonoma. Wikipedia. https://en.wikipedia.org/wiki/Glucagonoma. accessed on October 10, 2015
  2. Fang S, Li S, Cai T (2014). "Glucagonoma syndrome: a case report with focus on skin disorders". Onco Targets Ther. 7: 1449–53. doi:10.2147/OTT.S66285. PMC 4140234. PMID 25152626.


Template:WikiDoc Sources